AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg IV
Number of subjects: 90
Study 20974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 µg/kg IV
Number of subjects: 90
Study 20974320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18467723 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.5 mg/m2 (arm A)
Number of subjects: 102
Study 18467723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 plus irinotecan 125 mg/m2 (arm B)
Number of subjects: 102
Study 19250108 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apex stimulation
Number of subjects: 117
Study 19250108 — intervention group
Group type: COMPARATOR
Intervention: RV mid-septum stimulation
Number of subjects: 117
Study 15804736 — intervention group
Group type: EXPERIMENTAL
Intervention: ESTring
Number of subjects: 185
Study 15804736 — intervention group
Group type: COMPARATOR
Intervention: Vagifem
Number of subjects: 185
Study 15804736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 185
Study 11554655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily
Number of subjects: 80
Study 9457396 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 plus IFN-alpha
Number of subjects: 0
Study 9457396 — intervention group
Group type: EXPERIMENTAL
Intervention: DLI plus low-dose rIL-2
Number of subjects: 0
Study 9457396 — intervention group
Group type: COMPARATOR
Intervention: DLI
Number of subjects: 0
Study 9457396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rIL-2
Number of subjects: 0
Study 9457396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rIL-2 and IFN-alpha
Number of subjects: 0
Study 7897617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 20 mg
Number of subjects: 8
Study 7897617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 8
Study 7897617 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 3310792 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-fluidized beds (Clinitron Therapy)
Number of subjects: 72
Study 3310792 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Lapidus Air Float System)
Number of subjects: 72
Study 3310792 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-fluidized beds (for sores 7.8 cm2 or greater)
Number of subjects: 72
Study 3310792 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (for sores 7.8 cm2 or greater)
Number of subjects: 72
Study 3310792 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-fluidized beds
Number of subjects: 72
Study 31991216 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP)
Number of subjects: 282
Study 31765277 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enhanced reading therapy (14 hours)
Number of subjects: 21
Study 31765277 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed therapy)
Number of subjects: 21
Study 29855167 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraciliary implantation of hema implant (Esnoper V-2000)
Number of subjects: 83
Study 29855167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrascleral implantation of hema implant (Esnoper V-2000)
Number of subjects: 83
Study 29855167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 26579985 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy with lopinavir/ritonavir (400 mg/100 mg twice daily) plus either 2-3 clinician-selected nucleoside reverse transcriptase inhibitors, raltegravir, or as monotherapy after 12-week induction with raltegravir.
Number of subjects: 1036
Study 26579985 — intervention group
Group type: COMPARATOR
Intervention: Control group (first-line therapy failure).
Number of subjects: 1036
Study 24909636 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day meloxicam
Number of subjects: 56
Study 24909636 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day meloxicam
Number of subjects: 56
Study 24909636 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (not treated with meloxicam)
Number of subjects: 56
Study 21875167 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 512
Study 21875167 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 512
Study 18835411 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min brisk semi-self-paced brisk walk
Number of subjects: 25
Study 18835411 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 25
Study 17632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Marcaine infiltration
Number of subjects: 22
Study 17632138 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration (Control)
Number of subjects: 22
Study 15479936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive disease management from a multidisciplinary team for patients with low literacy.
Number of subjects: 217
Study 15479936 — intervention group
Group type: COMPARATOR
Intervention: Usual care after an initial management session for control patients.
Number of subjects: 217
Study 15479936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive disease management from a multidisciplinary team for patients with higher literacy.
Number of subjects: 217
Study 15479936 — intervention group
Group type: COMPARATOR
Intervention: Usual care after an initial management session for control patients with higher literacy.
Number of subjects: 217
Study 15479936 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 217
Study 11552189 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia with corticosteroid injection (lidocaine and betamethasone)
Number of subjects: 24
Study 11552189 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anesthesia without corticosteroid injection
Number of subjects: 24
Study 11360565 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medicine Syndrome Differentiation
Number of subjects: 60
Study 11360565 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 60
Study 7881451 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug
Number of subjects: 0
Study 7881451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3148148 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (AMP, 5 mg)
Number of subjects: 17
Study 3148148 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylpropanolamine (PPA, 75 mg)
Number of subjects: 17
Study 3148148 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylpropanolamine (PPA, 25 mg)
Number of subjects: 17
Study 28940882 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Onyx DES
Number of subjects: 75
Study 28940882 — intervention group
Group type: COMPARATOR
Intervention: Resolute DES (historical control)
Number of subjects: 75
Study 27083449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch for 6 weeks
Number of subjects: 269
Study 25257064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (B6, B12, folic acid)
Number of subjects: 153
Study 25257064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 23543661 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 8
Study 23543661 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 20378736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg)
Number of subjects: 16
Study 20378736 — intervention group
Group type: COMPARATOR
Intervention: MDMA (1.6 mg/kg)
Number of subjects: 16
Study 20378736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16
Study 18455087 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 16639665 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep lamellar keratoplasty
Number of subjects: 54
Study 16639665 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (Control)
Number of subjects: 54
Study 12582428 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin for 6 months (group A)
Number of subjects: 104
Study 12582428 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin for 12 months (group B)
Number of subjects: 104
Study 12582428 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin
Number of subjects: 104
Study 10458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Number of subjects: 0
Study 10458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with gemcitabine
Number of subjects: 0
Study 10458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel combined with ifosfamide
Number of subjects: 0
Study 10458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel within a sequential and concomitant chemoradiotherapy concept
Number of subjects: 0
Study 7536380 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination 24 hours before the second PSA determination
Number of subjects: 100
Study 7536380 — intervention group
Group type: COMPARATOR
Intervention: No urological manipulation between PSA determinations
Number of subjects: 100
Study 7536380 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 100
Study 2037789 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit (BS)‐whole‐cell vaccine
Number of subjects: 2713
Study 2037789 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐cell vaccine
Number of subjects: 2713
Study 2037789 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli K12 strain placebo
Number of subjects: 2713
Study 2037789 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 2713
Study 7307546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% pindolol eye drops
Number of subjects: 12
Study 7307546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% pindolol eye drops
Number of subjects: 12
Study 7307546 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 31843845 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1438
Study 31843845 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 1438
Study 25834963 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time training (JITT) instructional video
Number of subjects: 0
Study 25834963 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical textbooks)
Number of subjects: 0
Study 26434372 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing time
Number of subjects: 264
Study 26434372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic games
Number of subjects: 264
Study 26434372 — intervention group
Group type: EXPERIMENTAL
Intervention: Total screen-time
Number of subjects: 264
Study 23621793 — intervention group
Group type: EXPERIMENTAL
Intervention: BD32S4 needle (32 gauge×4 mm, straight wall)
Number of subjects: 84
Study 23621793 — intervention group
Group type: COMPARATOR
Intervention: TR33T5 needle (33-gauge tip and 28-gauge base×5 mm, double-tapered wall)
Number of subjects: 84
Study 23621793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 84
Study 22131607 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP autoSV Advanced
Number of subjects: 37
Study 22131607 — intervention group
Group type: COMPARATOR
Intervention: BiPAP autoSV
Number of subjects: 37
Study 22131607 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 37
Study 22131607 — intervention group
Group type: COMPARATOR
Intervention: PSG
Number of subjects: 37
Study 19842576 — intervention group
Group type: COMPARATOR
Intervention: Treatment modalities for psoriasis (exact treatments not specified) for 15 participants over 16 weeks followed by 12 weeks of observation.
Number of subjects: 21
Study 17578281 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilaterally-open expansive laminoplasty (group A)
Number of subjects: 138
Study 17578281 — intervention group
Group type: COMPARATOR
Intervention: Conventional unilaterally open-door laminoplasty (group B)
Number of subjects: 138
Study 15521902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 5‐20 mg 12 hourly
Number of subjects: 30
Study 15521902 — intervention group
Group type: COMPARATOR
Intervention: Tincture of opium (TOP) 3.33‐10 mg morphine equivalents 12 hourly
Number of subjects: 30
Study 11725824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tropisetron
Number of subjects: 60
Study 11725824 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 60
Study 11725824 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 60
Study 9874070 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen for 4 weeks
Number of subjects: 0
Study 9874070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7839305 — intervention group
Group type: EXPERIMENTAL
Intervention: Smectite
Number of subjects: 174
Study 7839305 — intervention group
Group type: COMPARATOR
Intervention: Control (motility modifying drugs)
Number of subjects: 174
Study 1699653 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP + low-dose bleomycin
Number of subjects: 274
Study 1699653 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 274
Study 1699653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (3 gm/m2/week intravenously with leucovorin rescue)
Number of subjects: 274
Study 1699653 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methotrexate (30 mg/m2/week orally without rescue)
Number of subjects: 274
Study 1699653 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular large cell lymphoma (with or without diffuse areas)
Number of subjects: 274
Study 356971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone
Number of subjects: 165
Study 356971 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease
Number of subjects: 165
Study 30210590 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast for 7 days
Number of subjects: 56
Study 26810526 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering (target systolic level < 140 mm Hg)
Number of subjects: 2630
Study 26810526 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target systolic level < 180 mm Hg)
Number of subjects: 2630
Study 24471991 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of lectures and reflective discussions
Number of subjects: 42
Study 24471991 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 42
Study 22187384 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation Group (RG)
Number of subjects: 44
Study 22187384 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoked Group (YG)
Number of subjects: 44
Study 22187384 — intervention group
Group type: COMPARATOR
Intervention: No Regulation Group (nRG)
Number of subjects: 44
Study 20887608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 26
Study 20887608 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 26
Study 18997461 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA-enriched diet (10.4 g TFAs for 4 days)
Number of subjects: 27
Study 18997461 — intervention group
Group type: COMPARATOR
Intervention: Return to habitual diet (1 week after TFA diet)
Number of subjects: 27
Study 18997461 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (0.8 g TFAs)
Number of subjects: 27
Study 16014054 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP (≥3.0 mg/L)
Number of subjects: 697
Study 16014054 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 697
Study 12852533 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐125 (0.87 mCi/source)
Number of subjects: 20
Study 12852533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd‐103 (2.54 U/source)
Number of subjects: 20
Study 12852533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both I‐125 and Pd‐103
Number of subjects: 20
Study 10551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCCs) 2000 factor IX units intravenously
Number of subjects: 16
Study 8887129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (1 microgram/kg up to 100 micrograms)
Number of subjects: 31
Study 8887129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 31
Study 8887129 — intervention group
Group type: COMPARATOR
Intervention: GnRH
Number of subjects: 31
Study 1341478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with corticoids (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) followed by interferon-alpha (2 MU, 3 times a week for 3 months)
Number of subjects: 60
Study 1341478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with corticoids (same dosage) followed by higher dose interferon-alpha (5 MU, 3 times a week)
Number of subjects: 60
Study 1341478 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU, 3 times a week for 4 months) without prior corticoids
Number of subjects: 60
Study 1341478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential corticoid/IFN therapy (both doses combined)
Number of subjects: 60
Study 1341478 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone therapy
Number of subjects: 60
Study 1341478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 6406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 59
Study 6406473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 3846924 — intervention group
Group type: EXPERIMENTAL
Intervention: Basin bath
Number of subjects: 40
Study 3846924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tub bath
Number of subjects: 40
Study 3846924 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower bath
Number of subjects: 40
Study 3846924 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified type of bath)
Number of subjects: 40
Study 30983166 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 3002
Study 30983166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3002
Study 29936922 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich diet (25% of energy)
Number of subjects: 15
Study 26765505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care protocol (tooth brushing, tongue scraping, flossing, mouth rinsing, lip care)
Number of subjects: 74
Study 26765505 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 26765505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care protocol
Number of subjects: 74
Study 25346506 — intervention group
Group type: EXPERIMENTAL
Intervention: New binge drinking standard (2-hour period)
Number of subjects: 368
Study 25346506 — intervention group
Group type: EXPERIMENTAL
Intervention: Old binge drinking standard (no time qualifier)
Number of subjects: 368
Study 22870898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner and four general practitioners providing care on one day of the weekend (10 am to 5 pm)
Number of subjects: 304000
Study 22870898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner and four general practitioners providing care
Number of subjects: 304000
Study 22870898 — intervention group
Group type: COMPARATOR
Intervention: Control group with five general practitioners providing care on another day of the weekend (10 am to 5 pm)
Number of subjects: 304000
Study 20567019 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) protracted intravenous infusion 300 mg/m² days 1 through 14 every 3 weeks (arm A)
Number of subjects: 44
Study 20567019 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization plus intravenous FU 225 mg/m² days 1 through 14 then 300 mg/m² days 1 through 14 every 3 weeks (arm B)
Number of subjects: 44
Study 18827631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion pump with Bupivacaine (0.375%) at 4 ml/hour
Number of subjects: 48
Study 18827631 — intervention group
Group type: COMPARATOR
Intervention: Control group with isotonic saline at 4 ml/hour
Number of subjects: 48
Study 18827631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion pump with Bupivacaine (0.375%)
Number of subjects: 48
Study 15858467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen intervention
Number of subjects: 309
Study 15858467 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study 12742278 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 114
Study 12742278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 10919936 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-restricted diet (<5 g/d sodium chloride)
Number of subjects: 39
Study 8670579 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 250 mg monthly injections
Number of subjects: 35
Study 8670579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1522491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release hydralazine with KCl
Number of subjects: 12
Study 1522491 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release hydralazine without KCl
Number of subjects: 12
Study 6731560 — intervention group
Group type: EXPERIMENTAL
Intervention: individual‐‐choice
Number of subjects: 40
Study 6731560 — intervention group
Group type: COMPARATOR
Intervention: individual‐‐no choice
Number of subjects: 40
Study 6731560 — intervention group
Group type: EXPERIMENTAL
Intervention: group‐‐choice
Number of subjects: 40
Study 6731560 — intervention group
Group type: COMPARATOR
Intervention: group‐‐no choice
Number of subjects: 40